SCHEMBL6408904

SCHEMBL6408904

C=C(C)[C@H]1Cc2c(cc(OC(C)=O)c3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 11/20 0.73
▸ MAPT P10636 8/20 0.73
▸ SMN1; SMN2 Q16637 8/20 0.73
▸ ALDH1A1 P00352 5/20 0.73
▸ KDM4E B2RXH2 5/20 0.73
▸ TDP1 Q9NUW8 5/20 0.73
▸ CYP2C19 P33261 4/20 0.73
▸ LMNA P02545 4/20 0.73
▸ MAPK1 P28482 4/20 0.73
▸ USP2 O75604 4/20 0.73
▸ TP53 P04637 4/20 0.73
▸ TSHR P16473 3/20 0.73
▸ MT-ND4 P03905 3/20 0.73
▸ CYP2C9 P11712 2/20 0.73
▸ NPC1 O15118 2/20 0.73
▸ RAB9A P51151 2/20 0.73
▸ CYP1A2 P05177 2/20 0.73
▸ HPGD P15428 2/20 0.73
▸ GMNN O75496 1/20 0.73
▸ ABCB11 O95342 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sumatrol SCHEMBL4739987 0.89 CYP3A4 (0.73) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Sumatrol SCHEMBL29929407 0.89 CYP3A4 (0.73) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL20152380 0.85 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL29351552 0.85 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL29388856 0.85 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL42253 0.85 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL9815546 0.85 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL13845713 0.85 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL19019920 0.85 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL13926662 0.85 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1151295-A4 METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS CYTOVIA INC (US) 2005-03-30 — — EP claimed
EP-1151295-A1 METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS Cytovia, Inc. (US) 2001-11-07 — — EP claimed
WO-2000045165-A1 METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS CYTOVIA, INC. (US) 2000-08-03 — — WO claimed
EP-1151295-A4 METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS CYTOVIA INC (US) 2005-03-30 — — EP disclosed
EP-1151295-A1 METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS Cytovia, Inc. (US) 2001-11-07 — — EP disclosed
WO-2000045165-A1 METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS CYTOVIA, INC. (US) 2000-08-03 — — WO disclosed
Send feedback